Natco to sell generic cancer drug in US

Hyderabad | Updated on January 12, 2018 Published on June 27, 2017

Natco Pharma has received final approval from the US Food and Drug administration (USFDA) for its Abbreviated New Drug Application for the generic version of Vidaza (Azacitidine for Injection). The Hyderabad-based Natco and its marketing partner Breckenridge Pharmaceutical, Inc. were planning to launch the product in the US market, the company said in a release. Vidaza by Celgene Corporation is a prescription anti-cancer chemotherapy drug that is indicated to treat, myelodysplastic syndrome. Vidaza generated total combined sales of $188 million for the 12 months ended April 2017, based on the industry sales data. Our Bureau

Published on June 27, 2017
This article is closed for comments.
Please Email the Editor